DeepMed Research

Gefitinib

Generic Name: Gefitinib

Brand Names: Iressa, Gefitinib Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄ClFN_₄O_₃

CAS Number: 184475-35-2

Unique Ingredient Identifier: S65743JHBS

Background: Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication: For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions: Metastatic Non-Small Cell Lung Cancer

Clinical Trials

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Phase 2

Conditions: Lung Adenocarcinoma

Interventions: Drug: Pemetrexed plus carboplatin combined with gefitinib
Drug: Gefitinib

First Posted Date: 2016-11-01

Last Posted Date: 2016-11-01

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 300

Registration Number: NCT02951637

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Phase 2

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: pemetrexed or gemcitabine plus carboplatin,
Drug: bevacizumab

First Posted Date: 2016-10-12

Last Posted Date: 2016-10-13

Lead Sponsor: Caicun Zhou

Target Recruit Count: 180

Registration Number: NCT02930954

Locations: 🇨🇳
Department of Oncology, Shanghai pulmonary hospital, Shanghai, China

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Phase 3

Conditions: Cancer

Interventions: Drug: gefitinib
Drug: Yiqi-yangyin-jiedu decoction
Drug: placebo

First Posted Date: 2016-10-11

Last Posted Date: 2019-04-11

Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Target Recruit Count: 198

Registration Number: NCT02929693

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Phase 3

Completed

Conditions: Cancer

Interventions: Drug: YiQiFang
Drug: placebo granules
Drug: Erlotinib®
Drug: YangYinFang
Drug: Gefitinib®
Drug: YiQiYangYinFang
Drug: Icotinib®

First Posted Date: 2016-09-05

Last Posted Date: 2019-04-11

Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Target Recruit Count: 23

Registration Number: NCT02889692

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)

Phase 3

Conditions: Stage IV EGFR Mutated NSCL With Brain Metastases

Interventions: Radiation: HFSRS
Radiation: WBRT

First Posted Date: 2016-08-30

Last Posted Date: 2016-08-30

Lead Sponsor: Sichuan Provincial People's Hospital

Target Recruit Count: 325

Registration Number: NCT02882984

Locations: 🇨🇳
Sichuan PPH, Cancer Center, Chengdu, Sichuan, China

Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)

Phase 2

Active, not recruiting

Conditions: NSCLC

Interventions: Drug: Osimertinib
Drug: Gefitinib

First Posted Date: 2016-08-05

Last Posted Date: 2022-09-15

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 156

Registration Number: NCT02856893

Locations: 🇫🇷
CHU de Brest, Brest, France
🇵🇱
Medical University of Gdansk, Gdansk, Poland
🇫🇷
Institut Paoli-Calmettes, Marseille, France

and more 19 locations

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Phase 2

Conditions: Gallbladder Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct

Interventions: Procedure: biological test
Drug: GEMOX
Drug: Cetuximab
Drug: Trastuzumab
Drug: Gefitinib
Drug: Lapatinib
Drug: Everolimus
Drug: Sorafenib
Drug: Crizotinib

First Posted Date: 2016-07-19

Last Posted Date: 2018-05-07

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 152

Registration Number: NCT02836847

Locations: 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Phase 3

Conditions: EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

Interventions: Drug: Apatinib
Drug: Placebo
Drug: Gefitinib

First Posted Date: 2016-07-06

Last Posted Date: 2016-07-07

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 246

Registration Number: NCT02824458

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2016-06-17

Last Posted Date: 2021-06-02

Lead Sponsor: National Cancer Centre, Singapore

Target Recruit Count: 15

Registration Number: NCT02804776

Locations: 🇸🇬
National Cancer Centre, Singapore, Singapore

Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?

Completed

Conditions: Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?

Interventions: Drug: Gefitinib

First Posted Date: 2016-04-15

Last Posted Date: 2016-04-15

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 100

Registration Number: NCT02740894

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy